BioSpace News Archive

Should you be looking for another job? Or are you actually in a good employment situation, and simply being carried away by others’ experiences on LinkedIn or Facebook?

At the American Society of Hematology meeting, companies are racing to develop a treatment for SCD, which is an inherited disorder caused by a genetic mutation in the beta-chain of hemoglobin. Some of the data presented by companies were promising, while others reported setbacks.

The new funding of $5 million per year for two years through to 2021 from the Industry Growth Centres initiative was announced today by Industry, Science and Technology Minister, Hon Karen Andrews MP at the Growth Centre Showcase at Parliament House in Canberra.

Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces results from the completion of its innovative pre-clinical trial for its NXP002 fibrosis programme in human idiopathic pulmonary fibrosis (‘IPF’) against standard of care

People who have managed to garner a large following on sites like Twitter, Facebook, Instagram, and the like have quite a bit of pull within said following. These “microcelebrities” are now a subject of interest for pharmaceutical companies who are looking for new ways to advertise their products.

It should come as no surprise that not all information on the internet is reliable. It’s a largely unregulated wild, wild west that allows for anyone to put up any content they wish to. Which can be a particular problem when it comes to health-related content.

Karolinska Development’s portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US.

A*STAR’s Institute of Microelectronics (IME) and One BioMed, an A*STAR spin-off, launched a S$9 million joint lab on Thursday (29 November).

At the 60th American Society of Hematology (ASH) Annual Meeting & Exposition, Amgen released the first clinical data from two separate Phase I clinical trials of novel BiTE immunotherapies.

Seattle Genetics and Takeda show off the impressive survival data that prompted the FDA to give approval to Adcetris for this indication.